Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Despite these assertions, there are credible questions about mammography. Just this year there have been a plethora of articles in various medical journals that highlight such potential downsides of screening mammography as overdiagnosis. As Dartmouth professor H. Gilbert Welch wrote in a British Medical Journal editorial this past July, overdiagnosis is a “vexing problem,” and causes some women to undergo unnecessary treatment. Welch, however, does not disparage mammography; instead, he writes, “Mammography is one of medicine's 'close calls'-a delicate balance between benefits and harms-where different people in the same situation might reasonably make different choices. Mammography undoubtedly helps some women but hurts others. No right answer exists; instead it is a personal choice.”
As I wrote in my April 2009 Diagnostic Imaging article, I believe there is sufficient, albeit not incontrovertible, evidence that mammography does reduce mortality from breast cancer, and that radiologists and other physicians should, after discussing both the pros and the cons of screening, encourage but not coerce women to undergo annual screening mammography. At the same time, however, acknowledging rather than denying the existence of controversies regarding mammography will assist the public at large to develop a realistic appraisal of mammography's role with regard to breast cancer.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
2 Commerce Drive
Cranbury, NJ 08512